CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 63 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $877,330 | +7211.1% | 29,500 | +6529.2% | 0.00% | – |
| Q4 2021 | $12,000 | -80.6% | 445 | -89.5% | 0.00% | -100.0% |
| Q1 2020 | $62,000 | -92.5% | 4,246 | -92.3% | 0.00% | -85.7% |
| Q3 2019 | $829,000 | -3.3% | 55,112 | +61.0% | 0.01% | 0.0% |
| Q2 2019 | $857,000 | -44.7% | 34,238 | -49.7% | 0.01% | 0.0% |
| Q1 2019 | $1,550,000 | – | 68,124 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |